Quick search:
Content Search
Result Content Research
Result Content Research
1 EQS-Adhoc : Polyphor to extend period for its strategic evaluation by up to four weeks
2 Idorsia announces financial results for the first half 2021 – Building momentum towards becoming a fully-fledged biopharmaceutical company
3 Polyphor to extend period for its strategic evaluation by up to four weeks
4 Idorsia announces the reference share price and the initial
5 Financings for July 28, 2021 | 2021-07-28
6 Idorsia holds its Annual General Meeting of Shareholders
7 Polyphor Announces Financial Results for the Full-Year 2020 2021-03-05 01:15 ALLSCHWIL, Switzerland
8 Idorsia to present new Phase 3 data on daridorexant in insomnia at SLEEP 2021
9 Idorsia reports results in relation to the Axovan arbitration – claim dismissed by Arbitral Tribunal
10 FDA accepts the new drug application for review of Idorsia's daridorexant for the treatment of adult
11 Idorsia issues Notice of the 2021 Annual General Meeting of
12 Basilea announces move of corporate headquarters to Allschwil, canton of Basel-Landschaft, in 2022
13 Idorsia announces the results of its rights offering in the context of the capital increase
14 After split from Actelion, Idorsia CEO plans to raise more cash in 2019
15 Polyphor's Balixafortide Demonstrates Consistent Dual Action Anti-Viral and Anti-Inflammatory Activity in COVID-19 Preclinical Trials
16 Idorsia to debut at the 39th JP Morgan Healthcare
17 Polyphor Receives Approval to Start First-in-Human Clinical Trial of Inhaled Antibiotic Murepavadin
18 Idorsia submits NDA for clazosentan to Japanese PMDA
19 US FDA approves Ponvory (ponesimod) to treat adults with
20 Idorsia submits European marketing authorisation application for daridorexant for the treatment of adult patients with insomnia
21 Idorsia successfully completes capital increase with gross proceeds of CHF 535.5 million
22 Idorsia initiates the Phase 3 registration study with selatogrel for the treatment of acute myocardial infarction
23 The European Medicines Agency's CHMP issues a positive opinion recommending marketing authorisation for Ponvory
24 Polyphor to Present at the UBS Global Healthcare Virtual Conference
25 Idorsia announces capital increase to prepare for the launch of daridorexant and further fund its diversified
26 Idorsia establishes US commercial operations and leadership team
27 Holiday Inn Express Announces New Hotel Openings in Europe
28 Primary School Gartenhof / BUR Architekten Primary School Gartenhof / BUR Architekten
29 Polyphor Announces Closing of Fosun Pharma Licensing Agreement for balixafortide in China and Receipt of $15 Million Upfront Payment
30 Priothera closes $35M series A round for pivotal trial to boost HSCT outcomes in AML
31 Exclusive: Fives Cryomec receives certification | News | gasworld
32 Polyphor completes recruitment in Phase III trial of balixafortide in metastatic breast cancer
33 Idorsia announces positive results of the two Japanese registration studies with clazosentan
34 Idorsia selects Syneos Health as commercialization partner
35 Daridorexant Phase 3 results in insomnia presented at SLEEP 2020
36 European Commission approves Ponvory (ponesimod) for the
37 Drug Maker Pays $360 Million to Settle Investigation Into Charity Kickbacks
38 Exclusive: Pharma firm exploited patient group to lobby NHS for drug approval
39 Idorsia successfully completes the offering of new shares thereby securing funding for the company's growth plan
40 Sorry, we're closed!
41 Johnson & Johnson refills drug cabinet with $30 billion Actelion deal
42 Actelion announces changes to its executive team upon completion of the transaction with Johnson & Johnson
43 Publication of Idorsia's prospectus relating to the listing of Idorsia Ltd on SIX Swiss Exchange
44 Idorsia and Mochida enter into a license agreement for the supply, co-development and co-marketing
45 Janssen submits European Marketing Authorization Application for ponesimod for treatment of adults with relapsing multiple sclerosis
46 Idorsia announces that Simon Jose is to join the company as Chief Commercial Officer
47 Janssen announces submission of New Drug Application to the U.S. FDA for ponesimod for treatment of
48 EMA gives green light to Actelion's Uptravi after safety review
49 How Sanofi lost out to J&J in $30 billion battle for Actelion
50 Neurocrine Biosciences and Idorsia amend option agreement
51 EMA panel recommends that use of Actelion's Uptravi may continue
52 J&J target Actelion could exit Swiss benchmark SMI index this month
53 Actelion redux? Fabry bid enters phase III as Idorsia working with full pipeline
54 Johnson & Johnson approaches Actelion about takeover deal
55 Science News Releases
56 Actelion shareholders back R&D spinoff, keep J&J deal on track
57 Phase 2 data of aprocitentan, Idorsia's dual endothelin receptor antagonist, presented at ESC 2019
58 Actelion sees Uptravi price of $160,000-170,000/patient
59 Johnson & Johnson Completes Acquisition of Actelion
60 Idorsia enters into a collaboration with Antares for the development of a novel self-administered drug
61 Idorsia announces collaboration with Janssen Biotech on aprocitentan
62 Efficacy and safety data with Idorsia's dual orexin receptor antagonist presented at SLEEP 2019 in San
63 Antibiotics with novel mechanism of action discovered
64 Actelion announces results of the MAESTRO study with macitentan in patients with pulmonary arterial hypertension due
65 Actelion shareholders snub Elliott bid for control
66 The Billion-Euro European Biotech Companies in 2018
67 Google Maps: fan of Spider-Man believed to capture the famous superhero, zoom and discover amazing secret ...